$CERO News

CERo Therapeutics Hldgs Q1 EPS $(0.20) Beats $(1.00) Estimate

CERo Therapeutics Completes Second Ascending Dose Cohort of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Third Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Doses Second Patient in Cohort 2 of Phase 1 CER-1236 Trial

CERo Therapeutics Provides Shareholder Update

CERo Therapeutics to Present Late-Breaking Oral Poster Session Highlighting Interim Phase 1 Data from CERTAIN-T Trial Highlighting Platelet Transfusion Independence in a High-Risk MDS/AML Patient

CERo Therapeutics Provides Clinical Update on Phase 1 Trial of CER-1236 in AML (CertainT-1) Highlighting Key Safety Data and Platelet Transfusion–Free Interval Observed in a Patient with Myelodysplastic Syndrome/AML

CERo Therapeutics Provides Clinical Update on Phase 1 Clinical Trial of CER-1236 in AML (CertainT-1)

CERo Therapeutics Announces Trading on OTCQB Market

CERo Therapeutics Hldgs Q3 EPS $(9.10) Misses $(2.94) Estimate

CERo Therapeutics Initiates Second Cohort of Phase 1 Clinical Trial of CER-1236 in AML with Patient Receiving Significant Increase in Dosing

CERo Therapeutics Holdings Initiated Second Cohort Of Phase 1 CER-1236 Clinical Trial Focused On Patients With Acute Myeloid Leukemia

CERo Therapeutics Holdings Initiated Second Cohort Of Phase 1 CER-1236 Clinical Trial Focused On Patients With Acute Myeloid Leukemia

CERo Therapeutics to Present Data at the Society for Immunotherapy of Cancer Conference Highlighting Lead Compound CER-1236 Sustained Cell Expansion and Cytokine Response

CERo Therapeutics To Present Preclinical Data On Its Lead Compound, CER-1236, Showing CER-1236 Exhibits Sustained Effector Function, Robust Cytokine Responses, And Resistance To Exhaustion Compared To Standard CD3/CD28 Stimulation

Maxim Group Downgrades CERo Therapeutics Hldgs to Hold

CERo Therapeutics Announces Listing on OTC Markets

CERo Therapeutics Shares To Continue To Trade Under Ticker CERO On OTC Markets

CERo Therapeutics Holdings shares are trading lower after the company announced the determination of the Nasdaq Hearings Panel to deny the request to continue the listing of its shares on the Nasdaq.

D. Boral Capital Maintains Buy on CERo Therapeutics Hldgs, Maintains $30 Price Target